• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多系统萎缩患者脑脊液生物标志物(包括神经元-神经胶质 2 和神经丝轻链)的临床相关性。

Clinical correlations of cerebrospinal fluid biomarkers including neuron-glia 2 and neurofilament light chain in patients with multiple system atrophy.

机构信息

Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan.

Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata, Japan.

出版信息

Parkinsonism Relat Disord. 2022 Sep;102:30-35. doi: 10.1016/j.parkreldis.2022.07.007. Epub 2022 Jul 30.

DOI:10.1016/j.parkreldis.2022.07.007
PMID:35933820
Abstract

BACKGROUND

Multiple system atrophy (MSA) is a progressive neurodegenerative disorder. The usefulness of biomarkers in diagnosing MSA has been recently reported, but few studies have investigated the correlations among cerebrospinal fluid (CSF) biomarkers or the relationship between CSF biomarkers and the clinical parameters of patients with MSA. Thus, this was the aim of our study.

METHODS

We performed cross-sectional study of CSF biomarkers in 50 patients with MSA and 20 control subjects. Ten of the patients with MSA were longitudinally followed for a period of 2 ± 1 years (mean ± standard deviation) as a substudy. We quantified CSF biomarkers including α-synuclein (α-syn), β-amyloid42 (Aβ42), total tau (t-tau) and phosphorylated tau (p-tau), neurofilament light chain (NfL), and neuron-glia2 (NG2), and assessed their relationship with clinical parameters (clinical subtypes, motor symptoms, nonmotor symptoms, and disease progression).

RESULTS

The levels of CSF α-syn, Aβ42, and p-tau were significantly lower, while those of NfL were higher in the patients with MSA than in the control subjects. Importantly, we found the significant elevation of soluble NG2 in the CSF of patients with MSA. CSF NfL showed the optimal diagnostic performance for MSA with levels at baseline significantly associated with longitudinal motor progression. With the exception of t-tau, there were no differences in the levels of CSF biomarkers between the MSA-parkinsonism and MSA-cerebellar subtypes.

CONCLUSIONS

Our results suggest CSF levels of NG2 and NfL as possible diagnostic and prognostic biomarkers in MSA. Further study is necessary to validate these findings.

摘要

背景

多系统萎缩(MSA)是一种进行性神经退行性疾病。生物标志物在 MSA 诊断中的作用最近已有报道,但很少有研究调查脑脊液(CSF)生物标志物之间的相关性或 CSF 生物标志物与 MSA 患者临床参数之间的关系。因此,这是我们研究的目的。

方法

我们对 50 例 MSA 患者和 20 例对照进行了 CSF 生物标志物的横断面研究。其中 10 例 MSA 患者作为亚组进行了为期 2±1 年的纵向随访。我们定量测定了 CSF 生物标志物,包括α-突触核蛋白(α-syn)、β-淀粉样蛋白 42(Aβ42)、总tau(t-tau)和磷酸化 tau(p-tau)、神经丝轻链(NfL)和神经元-胶质 2(NG2),并评估了它们与临床参数(临床亚型、运动症状、非运动症状和疾病进展)的关系。

结果

与对照组相比,MSA 患者的 CSF α-syn、Aβ42 和 p-tau 水平显著降低,而 NfL 水平显著升高。重要的是,我们发现 MSA 患者 CSF 中可溶性 NG2 显著升高。CSF NfL 对 MSA 具有最佳的诊断性能,基线水平与纵向运动进展显著相关。除 t-tau 外,MSA-帕金森病和 MSA-小脑亚型患者的 CSF 生物标志物水平无差异。

结论

我们的研究结果表明 CSF 中 NG2 和 NfL 水平可能是 MSA 的诊断和预后生物标志物。需要进一步的研究来验证这些发现。

相似文献

1
Clinical correlations of cerebrospinal fluid biomarkers including neuron-glia 2 and neurofilament light chain in patients with multiple system atrophy.多系统萎缩患者脑脊液生物标志物(包括神经元-神经胶质 2 和神经丝轻链)的临床相关性。
Parkinsonism Relat Disord. 2022 Sep;102:30-35. doi: 10.1016/j.parkreldis.2022.07.007. Epub 2022 Jul 30.
2
CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.脑脊液生物标志物β-淀粉样蛋白、tau 蛋白和α-突触核蛋白在帕金森病叠加综合征的鉴别诊断中的作用。
J Neurol Sci. 2017 Nov 15;382:91-95. doi: 10.1016/j.jns.2017.09.039. Epub 2017 Sep 28.
3
Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.多系统萎缩与帕金森病相比脑脊液中神经丝轻链水平的Meta分析
Neurol Sci. 2017 Mar;38(3):407-414. doi: 10.1007/s10072-016-2783-7. Epub 2016 Nov 28.
4
Associations of Multimorbidity with Cerebrospinal Fluid Biomarkers for Neurodegenerative Disorders in Early Parkinson's Disease: A Crosssectional and Longitudinal Study.早期帕金森病中多种疾病与神经退行性疾病脑脊液生物标志物的相关性:一项横断面和纵向研究。
Curr Alzheimer Res. 2024;21(3):201-213. doi: 10.2174/0115672050314397240708060314.
5
Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders.聚焦α-突触核蛋白相关疾病的10种生物标志物候选物的系统评估
Mov Disord. 2021 Dec;36(12):2874-2887. doi: 10.1002/mds.28738. Epub 2021 Aug 7.
6
Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.帕金森病脑脊液生物标志物的纵向测量
Mov Disord. 2016 Jun;31(6):898-905. doi: 10.1002/mds.26578. Epub 2016 Feb 16.
7
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.一组5种脑脊液生物标志物在痴呆和/或帕金森病患者鉴别诊断中的准确性
Arch Neurol. 2012 Nov;69(11):1445-52. doi: 10.1001/archneurol.2012.1654.
8
Combined CSF α-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again.联合 CSF α-SYN RT-QuIC、CSF NFL 和中脑脑桥平面图在变性帕金森病中的应用:从床边到实验室,再回到床边。
Parkinsonism Relat Disord. 2022 Jun;99:33-41. doi: 10.1016/j.parkreldis.2022.05.006. Epub 2022 May 13.
9
GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA).胶质纤维酸性蛋白(GFAP)和神经丝轻链(NfL)作为多系统萎缩(MSA)临床疾病严重程度和疾病进展的生物标志物。
J Neurol. 2024 Oct;271(10):6991-6999. doi: 10.1007/s00415-024-12647-z. Epub 2024 Sep 10.
10
Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis.液体生物标志物在多系统萎缩中的诊断效用:系统评价和荟萃分析。
J Neurol. 2021 Aug;268(8):2703-2712. doi: 10.1007/s00415-020-09781-9. Epub 2020 Mar 11.

引用本文的文献

1
Cerebrospinal fluid and blood neurofilament light chain in Parkinson's disease and atypical parkinsonian syndromes: a systematic review and Bayesian network meta-analysis.帕金森病和非典型帕金森综合征中的脑脊液和血液神经丝轻链:系统评价和贝叶斯网络荟萃分析
J Neurol. 2025 Apr 3;272(4):311. doi: 10.1007/s00415-025-13051-x.
2
Neurofilament Light Chain in Cerebrospinal Fluid and Blood in Multiple System Atrophy: A Systematic Review and Meta-Analysis.多系统萎缩患者脑脊液和血液中的神经丝轻链:一项系统评价和荟萃分析
Brain Sci. 2025 Feb 25;15(3):241. doi: 10.3390/brainsci15030241.
3
Comparison of inflammatory biomarker levels in neurodegenerative proteinopathies: a case-control study.
神经退行性蛋白质病中炎症生物标志物水平的比较:一项病例对照研究。
J Neural Transm (Vienna). 2025 Mar 3. doi: 10.1007/s00702-025-02902-6.
4
Integrative Analysis of Metabolome and Proteome in the Cerebrospinal Fluid of Patients with Multiple System Atrophy.多系统萎缩患者脑脊液中代谢组和蛋白质组的综合分析
Cells. 2025 Feb 12;14(4):265. doi: 10.3390/cells14040265.
5
The potential of phosphorylated α-synuclein as a biomarker for the diagnosis and monitoring of multiple system atrophy.磷酸化 α-突触核蛋白作为多系统萎缩诊断和监测标志物的潜力。
CNS Neurosci Ther. 2024 Apr;30(4):e14678. doi: 10.1111/cns.14678.
6
Serum neurofilament light chain levels in patients with cognitive deficits and movement disorders: comparison of cerebrospinal and serum neurofilament light chain levels with other biomarkers.认知缺陷和运动障碍患者的血清神经丝轻链水平:脑脊液和血清神经丝轻链水平与其他生物标志物的比较
Front Hum Neurosci. 2023 Dec 14;17:1284416. doi: 10.3389/fnhum.2023.1284416. eCollection 2023.
7
Diagnosing multiple system atrophy: current clinical guidance and emerging molecular biomarkers.多系统萎缩的诊断:当前临床指南与新兴分子生物标志物
Front Neurol. 2023 Sep 29;14:1210220. doi: 10.3389/fneur.2023.1210220. eCollection 2023.
8
Role of Oligodendrocyte Lineage Cells in Multiple System Atrophy.少突胶质细胞谱系细胞在多系统萎缩中的作用。
Cells. 2023 Feb 25;12(5):739. doi: 10.3390/cells12050739.
9
Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer's disease.α-突触核蛋白:阿尔茨海默病中的 Aβ 和 tau 病理因素及生物标志物。
Alzheimers Res Ther. 2022 Dec 31;14(1):201. doi: 10.1186/s13195-022-01150-0.